Navigation Links
Proscar Won't Boost Prostate Cancer Survival, Study Finds
Date:2/17/2013

By Steven Reinberg
HealthDay Reporter

FRIDAY, Feb. 15 (HealthDay News) -- Men with prostate cancer taking the drug finasteride (Proscar) don't survive longer than similar men not taking the drug, a new study finds.

Although Proscar is touted to reduce the odds of being diagnosed with prostate cancer, once diagnosed, men do not appear to gain a benefit from the drug, researchers say.

However, they don't face lowered survival from the drug, a researcher added.

"There is no evidence that finasteride is worse than placebo, in terms of overall survival," said lead author Phyllis Goodman, a biostatistician at the Fred Hutchinson Cancer Research Center, in Seattle.

"If you are inclined to give finasteride to prevent cancer, survival shouldn't be a reason not to do it," she said. "You may not be improving survival in the long run, but you are avoiding having to deal with a diagnosis of prostate cancer."

Based on the new finding, one expert doesn't recommend men take Proscar.

"This lessens the importance of finasteride, because if you wanted to use it as a preventive measure you hope the death rate would go down," said Dr. Anthony D'Amico, chief of genitourinary radiation oncology at Brigham and Women's Hospital, in Boston.

One problem with the study is that it deals with overall deaths -- not deaths specifically caused by prostate cancer. So it's hard to tell how effective Proscar really is, D'Amico said.

"Without a survival improvement it's hard to justify using the drug," he said. "Let me see what the cancer-specific survival looks like and then we can decide if it's appropriate at all."

The results of the study were presented Thursday at the annual Genitourinary Cancers Symposium in Orlando, Fla. The data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

For the U.S. National Cancer Institute-funded study, researchers collected data on deaths of men taking Proscar or an inactive placebo who were located in a Social Security database of deaths.

The investigators found that among 18,000 men who had been taking Proscar for seven years, there were more than 5,000 deaths. Of these, 2,584 deaths were among men taking Proscar and 2,544 deaths were among men taking placebo.

Over 15 years of follow-up, the survival rate was 78 percent for men in both groups, the study found.

Although men suffering from the most aggressive prostate cancers saw no benefit from Proscar, men with less aggressive cancer taking the drug did have a significant survival advantage, compared to men receiving placebo, the researchers found.

In 2011, the U.S. Food and Drug Administration placed a black-box warning on Proscar for a slight but statistically significant risk that its use could cause aggressive prostate cancer. The drug has several side effects including impotence and loss of interest in sex.

In the new study, the bottom line for the researchers is that "finasteride administration for seven years does not appear to affect mortality but significantly reduces the risk of a prostate cancer diagnosis."

Another expert gave his perspective on the drug.

"At this point, I think that the data is showing that the drug may not be of any significance to patients," said Dr. Louis Kavoussi, chairman of urology at North Shore-LIJ Arthur Smith Institute for Urology in New Hyde Park, N.Y.

However, Proscar may slow the progression of prostate cancer, he said.

"There are individuals who may benefit from being put on this drug and may rest a little bit easier at night knowing that it may not have a negative outcome on their long-term survival," Kavoussi said.

More information

To learn more about prostate cancer, visit the American Cancer Society.

SOURCES: Phyllis Goodman, Fred Hutchinson Cancer Research Center, Seattle; Anthony D'Amico, M.D., Ph.D., chief, genitourinary radiation oncology, Brigham and Women's Hospital, Boston; Louis Kavoussi, M.D., chairman of urology, North Shore-LIJ Arthur Smith Institute for Urology, New Hyde Park, N.Y.; Feb. 14, 2013, presentation, 2013 Genitourinary Cancers Symposium, Orlando, Fla.


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Avastin May Help Boost Survival With Aggressive Cervical Cancer: Study
2. A Good Mood May Boost Seniors Brain Power
3. Living Near Equator May Boost Your Risk for Allergy, Asthma
4. Personalized plans to address barriers to HIV drug adherence boost chances of successful therapy
5. Fried Foods May Boost Prostate Cancer Risk, Study Says
6. Plastic Surgery Practice Gets Boost from Lower Eyelid Surgery Webinar
7. Get Bigger Buttocks
8. How “Bigger Butt Secrets” Helps Women Boost Their Butt Naturally – Tony Nguyen
9. Diet, parental behavior, and preschool can boost childrens IQ
10. Oxygen chamber can boost brain repair
11. Cognitive Decline May Be Reversible with Brain-Boosting Vitamins
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Proscar Won't Boost Prostate Cancer Survival, Study Finds
(Date:8/18/2017)... ... 18, 2017 , ... Inc. magazine has ranked American Specialty Health, Incorporated (ASH) ... nation's fastest-growing private companies. This marks the eighth time in the last nine years ... year’s ranking reflects ASH’s 76 percent overall revenue growth from 2013 ($239 million) through ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Three Narrow Roads”: a vivid ... creation of published author, Rev. Dr. Burnett King Sr., is currently the pastor-teacher-visionary at ... of the Faith Track Club, Inc., a track-and-field program geared towards youth. , King ...
(Date:8/18/2017)... ... ... “Kingdom Mandate for Kingdom Builders”: a call to walk as citizens of the ... creation of published author, John F. McGeorge, Jr. Dr. John F. McGeorge Jr., ... He spent three decades training pastors and Christian leaders. He also met his ...
(Date:8/17/2017)... Goldsboro, NC (PRWEB) , ... August 17, 2017 ... ... multi-specialty dental practice, is adding a new location in Goldsboro, NC to its ... trusted care that is Riccobene Associates’ trademark starting August 15, 2017. , ...
(Date:8/17/2017)... ... 17, 2017 , ... Industry CEOs, life science leaders, influential ... This off-the-record networking forum of the Boston Biotech Conference series will be held ... leaders and decision makers will discuss issues facing the development of anti-infective, antiviral, ...
Breaking Medicine News(10 mins):
(Date:8/18/2017)... , Aug. 18, 2017  Nortis today announced the ... funding for the third year of a Small Business ... National Institute of Neurological Disorders and Stroke (NINDS).?  ... Nortis ParVivo ... ...
(Date:8/17/2017)... 2017 MJAC2017 , the premier cannabis event ... today reveals its leading lineup. MJAC2017 ... cannabis innovator specializing in the development of pharmaceutical and consumer ... Rambridge™ and The Green Organic Dutchman are gold sponsors for ... silver sponsors. ...
(Date:8/17/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading ... big data solutions, announced today that it has ... investors for the sale of shares of the ... newly designated Series B Convertible Preferred Stock in ... conduct a closing with respect to the offerings ...
Breaking Medicine Technology: